QUANTUM HEALTHCARE LIMITED
(Company Registration No. 202218645W)
(Incorporated in the Republic of Singapore)

RECEIPT OF LETTER OF DEMAND AGAINST QT VASCULAR LTD, WHOLLY-OWNED SUBSIDIARY OF THE COMPANY

The board of directors ("**Board**" or "**Directors**") of Quantum Healthcare Limited (the "**Company**", and together with its subsidiaries, the "**Group**") wishes to inform shareholders of the Company ("**Shareholders**") that QT Vascular Ltd. ("**QTV**"), a wholly-owned subsidiary of the Company, has on 30 October 2026 received a letter of demand ("**Letter**") from the solicitor representing Mr. Sho Kian Hin ("**Mr. Sho**"), a former director of QTV, and subsequently that of the Company, following the completion of the scheme of arrangement, in relation to the outstanding director's fees of USD120,000 owing by QTV to Mr Sho for his tenure of service for the financial years ended 2019 and 2020 ("**Outstanding Sum**").

Under the Letter, Mr Sho's solicitor has, *inter alia*, demanded for payment in full of the Outstanding Sum to Mr Sho within 14 days from the date of the Letter failing which they shall take such steps as necessary to recover the Outstanding Sum without further notice, including commencing legal proceedings against QTV.

The Board also refers to its announcement dated 8 October 2026 in relation to the proposed disposal of QTV to EP Systems Sdn. Bhd. (the "**Purchaser**") under the sale and purchase agreement dated 8 October 2026 (the "**SPA**") (the "**Proposed Disposal**").

The claim for payment of the Outstanding Sum under the Letter ("**Claim**") should not have a material impact on the Proposed Disposal, *inter alia,* as it was expressly agreed under the terms of the SPA that the Proposed Disposal would be on an "*as is where is*" basis, and QTV's potential liability for the Outstanding Sum was also expressly disclosed and made known to the Purchaser under the terms of the SPA. As such, the Purchaser would not legally have a basis to rescind or terminate the SPA, or otherwise not proceed to complete the purchase of the Sale Shares by reason of the Claim.

Nevertheless, the Company has informed the Purchaser of the receipt of the Letter and will explore possible action(s) to be taken in relation to the Claim.

The Company will provide further updates to Shareholders, as and when there are any material developments on this matter.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the securities of the Company and to refrain from taking any action in relation to their shares which may be prejudicial to their interests. In the event of any doubt about the actions to be taken, shareholders and potential investors of the Company should consult their stockbrokers, bank managers, solicitors, accountants and other professional advisers.

By Order of the Board
QUANTUM HEALTHCARE LIMITED

Gian Siong Lin Jimmy
Executive Chairman and Chief Executive Officer
2 November 2026

This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. ("**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited ("**Exchange**") and the Exchange assumes no responsibility for the contents of this announcement, including the correctness of any of the statements or opinions made or reports contained in this announcement.

The contact person for the Sponsor is Ms Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.